Clinical Trials Logo
  1. Home
  2. Lung Transplant Rejection
  3. NCT06309628

Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy

Lung Transplant Rejection Clinical Trial

Official title:
Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection

Clinical Trial Summary

This study will sample and analyze volatile organic compounds (VOCs) from participants considered to be at risk for developing rejection following lung transplant by using infrared spectroscopy.

Clinical Trial Description

The aim of this study is to sample and analyze volatile organic compounds (VOCs) from participants considered to be at risk for developing rejection following lung transplant. By using infrared spectroscopy, the breath sample analysis will help investigators describe and identify patterns of VOCs that are over- or under-represented in patients with post-lung transplant rejection when compared to the breath profiles of those without rejection. It is hypothesized that the profile of volatile chemicals in the breath of patients in the early stages of rejection will differ significantly from those individuals without rejection. Primary objective • To analyze the breath-born VOCs in breath profiles of lung transplant patients with rejection in comparison to lung transplant patients without rejection using infrared spectroscopy to determine the presence of lung rejection and to develop mathematical/statistical models of infrared absorption spectrum for identification of rejection. Secondary objective - To determine the best method to classify health status based on VOC data of breath samples - To validate early test results on an additional infrared spectroscopic analyzer in post-lung transplant patients The study is an unblinded, prospective case-control study. The study cohorts will include: 1) patients with confirmed post-lung transplant rejection via biopsy, and 2) control patients who have undergone lung transplant but are free from rejection as confirmed via biopsy. Breath samples collected from participants will be analyzed to characterize and further identify differences in infrared absorption profiles from each cohort using infrared spectroscopy. The data will be used to validate a previously developed machine learning algorithm. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06309628
Study type Observational
Source Paragonix Technologies
Contact
Status Enrolling by invitation
Phase
Start date September 21, 2023
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT02893176 - Macitentan in the Treatment of Organ Rejection After Lung Transplantation Phase 4
Completed NCT02441413 - Transplant Optimization Using Functional Imaging (TROFI) N/A
Recruiting NCT05375149 - Exhaled Breath Particles in Lung Transplantation
Active, not recruiting NCT03967340 - PREdiction of Chronic LUng Allograft Dysfunction
Active, not recruiting NCT05260372 - Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Recruiting NCT06082037 - A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction Phase 3
Recruiting NCT04714801 - Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation Phase 1/Phase 2
Active, not recruiting NCT05170425 - LAMBDA 002 (Lung Registry) Study
Completed NCT02474927 - Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Phase 2
Recruiting NCT05006742 - Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients N/A
Recruiting NCT02812290 - Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
Not yet recruiting NCT03500575 - Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients N/A
Withdrawn NCT03805178 - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization Phase 2
Completed NCT03359863 - Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction Phase 2
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Completed NCT01985412 - Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
Completed NCT04234919 - Longitudinal Study of Cell Free DNA in Lung Transplant
Recruiting NCT04837339 - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation N/A
Recruiting NCT03090581 - Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation. N/A
Recruiting NCT06112951 - A Prospective Randomized Trial of ECP in Subclinical AMR N/A